: iStockAnalyst.com Symbols Feed

BioMed News Bytes: BSD Medical, Provectus, Incyte, OncoMethylome

Tue, 22 Sep 2009 16:37:17 GMT

On 9/21/09, Provectus Pharma (OTC: PVCT.OB) ($0.96, +1%, above-average volume on 21-Sep) announced that it completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma. The primary objective of the Phase 2 study is to investigate the effectiveness of intralesional (IL) PV-10[More...]

Hot Stocks Of The Day: AIG, INCY, MOLX, POT, BUSE

Mon, 21 Sep 2009 18:47:03 GMT

US stocks retreated on Monday as stronger dollar weighed on energy and materials stocks. However, Nasdaq Composite turned higher in midday trade, boosted by a rally in biotech shares.[More...]

Bullish Stocks To Watch For The Week Of August 31, 2009

Mon, 31 Aug 2009 17:55:14 GMT

In this post is a list of 13 stocks that I'll be keeping an eye on for the week ahead. All of the stocks mentioned in this post are stocks which have broken out to the upside on unusually large volume. The table below shows the company, ticker, Friday's per share % increase, and Friday's volume increase (% increased compared to 50 day average).[More...]

Biotech Portfolio Updates – Incyte (NASDAQ: INCY)

Tue, 11 Aug 2009 13:53:37 GMT

A drug with an almost certain approval and immediate sales potential of hundreds of millions of dollars is an asset very few biotech companies possess. In that sense, Incyte (INCY), which is developing a breakthrough drug for blood[More...]

Surging Markets Disregard Negative Divergences and Overbought Oscillators

Thu, 23 Jul 2009 23:29:26 GMT

The market had an extremely strong session on Thursday, and the rally rolls on. The day started out with a move up off the opening, and just accelerated from there, reaching the session highs around early afternoon. They pulled back to test the intraday moving averages successfully, and then moved back up to retest the highs, creating doubletops at 1605 NDX and just under 980 SPX. In the last half hour or so they gave back a bit of it, but still closed strong. Net on the day the Dow was up over 188 points at 9069.29, the S&P 500 up 22.22 at 976.29, and the Nasdaq 100 up 36.52 at 1601.52. Advance-declines were better than 5 to 1 positive on New York and about 3 ½ to 1 positive on Nasdaq. Up/down volume was more than 1.1 billion to the upside and 225 million to the downside, about 4 ½ to 1 positive, on New York. Nasdaq traded a heavy 3 billion shares and had an[More...]

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Fri, 29 May 2009 12:08:55 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

Morphosys – A Biotech Rule Breaker

Tue, 31 Mar 2009 20:40:00 GMT

Morphosys (MOR.DE) is one of the most unusual biotech companies, as it breaks three basic rules that apply to drug development companies: